Success Metrics

Active Trials
2(67%)

Phase Distribution

Ph phase_2
1
33%
Ph phase_1
2
67%

Phase Distribution

2

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
2(66.7%)
Phase 2Efficacy & side effects
1(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

3

all time

Status Distribution
Active(2)
Other(1)

Detailed Status

Active, not recruiting2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
2
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Phase 12 (66.7%)
Phase 21 (33.3%)

Trials by Status

active_not_recruiting267%
unknown133%

Recent Activity

2 active trials
Showing 3 of 3
active_not_recruitingphase_1

Haploidentical PBMC Transplant for Severe Congenital Anemias

NCT00977691
active_not_recruitingphase_2

Concomitant Radiotherapy, Tremelimumab & Durvalumab for Advanced NSCLC Patients Progressing on First-line Immunotherapy

NCT05000710
unknownphase_1

Maintenance Ipilimumab + Nivolumab Post Induction Chemotherapy + SBRT for First Line Treatment Stage IV Pancreatic Cancer

NCT05088889

Clinical Trials (3)

Showing 3 of 3 trials
NCT00977691Phase 1

Haploidentical PBMC Transplant for Severe Congenital Anemias

Active Not Recruiting
NCT05000710Phase 2

Concomitant Radiotherapy, Tremelimumab & Durvalumab for Advanced NSCLC Patients Progressing on First-line Immunotherapy

Active Not Recruiting
NCT05088889Phase 1

Maintenance Ipilimumab + Nivolumab Post Induction Chemotherapy + SBRT for First Line Treatment Stage IV Pancreatic Cancer

Unknown

All 3 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
3